Bicara Therapeutics (NASDAQ: BCAX) Cancer Program & Strong Cash

Font: Financial Modeling Prep  • Aug 18, 2026

Bicara Therapeutics (NASDAQ: BCAX) Advances Cancer Program with Pivotal Trial and Strong Cash Position

• Bicara Therapeutics is enrolling the Phase 3 portion of its pivotal FORTIFI-HN01 trial of ficerafusp alfa, with topline interim results expected in mid-2027.
• BMO Capital initiated coverage with an Outperform rating and a $35 price target, while BTIG raised its target to $39.
• The company held $497.3 million in cash, cash equivalents, and marketable securities, which it expects will fund operations into the first half of 2029.

Bicara Therapeutics (NASDAQ: BCAX) is a clinical-stage biopharmaceutical company developing bifunctional therapies for solid tumors. Its lead drug candidate, ficerafusp alfa, is being evaluated primarily as a potential treatment for head and neck cancer. As of August 18, 2026, the company had a market capitalization of approximately $1.65 billion.

On August 18, 2026, BMO Capital initiated coverage of Bicara Therapeutics with an Outperform rating and a $35 price target. BCAX shares closed at $24.92 that day.

The company is advancing ficerafusp alfa in FORTIFI-HN01, a pivotal Phase 2/3 clinical trial in first-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma. Bicara is currently enrolling the Phase 3 portion of the study and expects substantial enrollment by the end of 2026, enabling topline results from an interim analysis in mid-2027. The company believes the interim results could potentially support an accelerated approval application.

Financially, Bicara reported $497.3 million in cash, cash equivalents, and marketable securities as of June 30, 2026. Based on its current operating and development plans, the company expects these resources to fund operations into the first half of 2029.

Bicara reported a second-quarter net loss of $55.4 million, or $0.82 per share, compared with a net loss of $27.4 million, or $0.50 per share, in the prior-year period. The per-share loss was slightly smaller than the analyst consensus estimate of $0.84.

Other analysts revised their price targets following the results. BTIG analyst Jeet Mukherjee maintained a Buy rating and raised the price target from $28 to $39. Wells Fargo analyst Eva Fortea-Verdejo maintained an Equal-Weight rating and increased the price target from $16 to $23.

The financial and trial details are confirmed by Bicara’s Q2 2026 release, while the BTIG and Wells Fargo changes were reported by Benzinga.